MA71666A - Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés - Google Patents

Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés

Info

Publication number
MA71666A
MA71666A MA71666A MA71666A MA71666A MA 71666 A MA71666 A MA 71666A MA 71666 A MA71666 A MA 71666A MA 71666 A MA71666 A MA 71666A MA 71666 A MA71666 A MA 71666A
Authority
MA
Morocco
Prior art keywords
scd5
stearoyl
methods
rnai agent
agent compositions
Prior art date
Application number
MA71666A
Other languages
English (en)
Inventor
Adam CASTORENO
James D. Mcininch
Lan Thi Hoang DANG
Original Assignee
Alnylam Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals, Inc. filed Critical Alnylam Pharmaceuticals, Inc.
Publication of MA71666A publication Critical patent/MA71666A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14212—Pumping with an aspiration and an expulsion action
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/19—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with oxidation of a pair of donors resulting in the reduction of molecular oxygen to two molecules of water (1.14.19)
    • C12Y114/19001—Stearoyl-CoA 9-desaturase (1.14.19.1), i.e. DELTA9-desaturase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA71666A 2021-03-18 2022-03-17 Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés MA71666A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163162788P 2021-03-18 2021-03-18
US202163278389P 2021-11-11 2021-11-11
EP22772237.8A EP4308130A4 (fr) 2021-03-18 2022-03-17 Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés
PCT/US2022/020825 WO2022197975A1 (fr) 2021-03-18 2022-03-17 Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés

Publications (1)

Publication Number Publication Date
MA71666A true MA71666A (fr) 2025-05-30

Family

ID=83320836

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71666A MA71666A (fr) 2021-03-18 2022-03-17 Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés

Country Status (4)

Country Link
US (1) US20240200077A1 (fr)
EP (1) EP4308130A4 (fr)
MA (1) MA71666A (fr)
WO (1) WO2022197975A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014782A2 (fr) * 2003-06-13 2005-02-17 Alnylam Europe Ag., Acide ribonucleique double brin presentant une efficacite accrue dans un organisme
US20070161003A1 (en) * 2003-09-29 2007-07-12 Morris David W Novel therapeutic targets in cancer
AU2010223967B2 (en) * 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
CN103361352A (zh) * 2013-07-31 2013-10-23 扬州大学 鹅原代肝细胞scd1基因沉默试剂盒及其应用
CA3049010A1 (fr) * 2017-01-06 2018-07-12 Yumanity Therapeutics, Inc. Methodes de traitement de troubles neurologiques

Also Published As

Publication number Publication date
EP4308130A1 (fr) 2024-01-24
EP4308130A4 (fr) 2025-09-17
WO2022197975A1 (fr) 2022-09-22
US20240200077A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
EP3962296A4 (fr) Compositions de cannabinoïdes et procédés d'utilisation
EP4329757A4 (fr) Composés hétérocycliques et procédés d'utilisation
MA52390A (fr) Anticorps anti-coronavirus et procédés d'utilisation
EP3890736A4 (fr) Agents de dégradations de petites molécules de helios et procédés d'utilisation
EP4291193A4 (fr) Agents de dégradation d'egfr et procédés d'utilisation
EP3752166A4 (fr) Agents de liaison trialcyne et procédés d'utilisation
EP4329521A4 (fr) Compositions de collagène et leurs procédés d'utilisation
EP4255403A4 (fr) Compositions de cannabinoïde à pénétration rapide, procédés de fabrication et méthodes d'utilisation
EP4168541A4 (fr) Mutéines ace2 et procédés d'utilisation de celles-ci
EP3917543A4 (fr) Compositions de nitrate améliorées et procédés d'utilisation
MA55381A (fr) Pyridazinones et leurs procédés d'utilisation
EP4208445A4 (fr) Dérivés de psilocybine halogénés et leurs procédés d'utilisation
EP3996714A4 (fr) Formulations d'inhibiteurs de rbp4 et procédés d'utilisation
EP4069726A4 (fr) Agonistes du récepteur glp2 et méthodes d'utilisation
EP3952896A4 (fr) Compositions et méthodes d'utilisation du senecavirus (svv) pour traiter le cancer
EP4161921A4 (fr) Inhibiteurs de traduction du collagène 1 et leurs procédés d'utilisation
EP4346815A4 (fr) Composés hétérocycliques et procédés d'utilisation
EP4157456A4 (fr) Réplicons d'arn encapsulés et procédés d'utilisation
EP3765005A4 (fr) Inhibiteurs de l'intégrine alpha 2 bêta 1 et procédés d'utilisation
EP3965776A4 (fr) Compositions oligosaccharidiques et leurs procédés d'utilisation
EP4322916A4 (fr) Compositions de traitement capillaire et procédés d'utilisation
EP4423116A4 (fr) Procédés et compositions pour le traitement du glioblastome
EP4370537A4 (fr) Compositions comprenant des peptides multi-agonistes, procédés de fabrication et méthodes d'utilisation
EP4294454A4 (fr) Peptides anti-viraux et compositions et procédés d'utilisation associés
MA50798A (fr) Procédés d'utilisation et compositions contenant du dulaglutide